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Introduction
Chronic lung injury resulting from a variety of differ-
ent causes is frequently associated with the development of 
pulmonary fibrosis, which is characterized by replacement 
of the normal alveolar structure by a thickened extracel-
lular matrix (ECM) with consequent reduction in the ca-
pacity for gas exchange1. Interstitial lung diseases (ILDs), 
more accurately known as diffuse parenchymal lung dis-
eases (DPLDs), are a diverse group of pulmonary disorders, 
which  include  idiopathic  interstitial  pneumonias  (IIPs), 
drug-induced  ILDs  and  occupational  and  environmental 
lung diseases2. IIPs are categorized as heterogeneous clini-
copathologic  disorders,  which  include  nonspecific  inter-
stitial  pneumonia  (NSIP),  respiratory  bronchiolitis  (RB)/
RB-associated  ILD  (RB-ILD),  cryptogenic  organizing 
pneumonia (COP)/organizing pneumonia (OP), desquama-
tive interstitial pneumonia (DIP), lymphocytic interstitial 
pneumonia (LIP), acute interstitial pneumonia (AIP)/diffuse 
alveolar damage (DAD) and idiopathic pulmonary fibrosis 
(IPF)/usual interstitial pneumonia (UIP), which have been 
defined by the American Thoracic Society/European Respi-
ratory Society consensus classification3–5 (Table 1). IPF/UIP 
is the most common disorder among the IIPs, characterized 
by unrelenting progression of fibrosis; DIP and RB-ILD are 
related pathologically; and AIP, characterized by an acute 
onset of respiratory symptoms, is analogous to acute respi-
ratory distress syndrome, differing only in that it is not pre-
ceded by an identifiable catastrophic event5.
Although the etiology of IPF is generally unknown, 
several sources of evidence support the hypothesis that a 
number of environmental and occupational agents such as 
cigarette smoke, agriculture/farming, livestock, wood dust, 
metal dust and stone/sand play an etiologic role in the patho-
genesis of this disease6. With respect to occupational and 
environmental lung diseases, the industrial revolution of the 
19th century resulted in widespread exposure to dust, which 
promoted the development of diseases such as silicosis, coal 
workers’ pneumoconiosis and asbestosis; however, improve-
ment in working conditions resulted in a decrease in the in-
cidence of these lung diseases2. In the past 20–30 years, an 
increase in industrial processes has led to the production 
and use of a large number of chemicals, some of which are 
currently reported as causes of ILDs (e.g., beryllium, nylon 
flock,  textile  printing  aerosols,  polyvinyl  chloride  (PVC) 
and organic vapors from flavorings). Sarcoidosis, a distinct 
entity of ILDs, is a granulomatous disease of unknown eti-
ology, occurring most commonly in the lung; however, non-
infectious environmental agents (e.g., beryllium, aluminum 
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and zirconium) can produce pulmonary lesions similar to 
those of sarcoidosis2. The agents discussed in this review 
include  beryllium,  nylon  flock,  textile  printing  aerosols, 
PVC  and  didecyldimethylammonium  chloride  (DDAC) 
(Table 2). Common ILD-causing drugs include amiodarone, 
antibiotics, nonsteroidal anti-inflammatory drugs, chemo-
therapeutic agents (e.g., bleomycin and methotrexate) and 
nitro drugs, all of which can produce virtually all the his-
topathologic patterns  of  interstitial pneumonia, including 
NSIP, OP, DIP and a pulmonary granulomatosis-like reac-
tion7. However, this review does not include drug-induced 
ILDs, except for a bleomycin animal model, for discussing 
the mechanism of pulmonary fibrosis.
The  pathogenesis  of  pulmonary  fibrosis  is  complex, 
involving innate and adaptive immunoreactions against ex-
ogenous environmental cues and subsequent molecular and 
cellular responses, leading to an imbalance of profibrogenic 
and antifibrogenic effects in healing processes. This review 
also focuses on specific pathobiological mediators such as 
chemokines  and  chemokine  receptors,  regulatory  T  cells 
(Tregs) and transforming growth factor-b (TGF-b) and bone 
morphogenetic protein (BMP) signaling.
Beryllium
Beryllium,  which  mostly  occurs  naturally  as  beryl-
lium aluminum silicate, is the fourth lightest element, hav-
ing a low density (1.85 g/cm3 at 20 °C), high melting point 
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Table 1.  Histopathological Pattern of Interstitial lung Diseases (ILD)3–5
Clinical diagnosis Pathology Key features
NSIP NSIP Cellular pattern: Mild to moderate interstitial chronic inflammation with hyperplasic 
pneumocytes.
Fibrosing pattern: Diffuse thickening of alveolar walls by dense or loose connective tissues 
and interstitial chronic inflammation (basically lacking the UIP pattern and preserving 
alveolar architecture).
RB RB-ILD Bronchiolocentric accumulation of alveolar macrophages (laden iron) with mild bronchiolar 
fibrosis and chronic inflammation.
COP OP Patchy plugs of loose connective tissues within a bronchiole, the adjacent alveolar ducts 
and alveolar spaces and with mild interstitial chronic inflammation.
DIP DIP Marked alveolar accumulation of macrophages (laden iron) with mild interstitial thickening 
and chronic inflammation.
LIP LIP Diffuse thickening of alveolar walls by infiltration of T cells, plasma cells and macrophages 
and MALT hyperplasia.
AIP DAD Diffuse alveolar wall thickening by proliferation of connective tissues, inflammation and 
deposition of hyaline membranes.
IPF UIP Patch fibrosis with remodeling of the lung structures, fibroblast foci, dense collagenous 
scaring, overlying hyperplasic pneumocytes and cystic changes (honeycomb change lined 
by columnar respiratory epitheliums).
NSIP, nonspecific interstitial pneumonia; RB, respiratory bronchiolitis; RB-ILD, RB-associated with ILD; COP, cryptogenic organizing 
pneumonia; OP, organizing pneumonia; DIP, desquamative interstitial pneumonia; LIP, lymphocytic interstitial pneumonia; MALT, mucosa-
associated lymphoid tissue; AIP, acute interstitial pneumonia; DAD, diffuse alveolar damage; IPF, idiopathic pulmonary fibrosis; UIP, usual 
interstitial pneumonia.
Table 2.  Environmental and Occupational Agents and Pulmonary Fibrosis
Chemicals Disease Key factors/Mechanism References
Beryllium ABD/CBDΨ Hypersensitivity, oxidative stress 10, 11, 16, 23, 24
Nylon flock Flock Worker's Lung# Hypersensitivity, iron-mediated 30–32
Textile paint Ardystil syndromeξ Acramine F 37–41
PVC Pulmonary fibrosisΨ Residual additives, eosinophilia 43–45, 50–52
DDAC ¶ Cytotoxicity, inflammation 63–65, 69
PVC, polyvinyl chloride; DDAC, didecyldimethylammonium chloride; ABD, acute beryllium disease; CBD, chronic 
beryllium disease.# Diagnosed as lymphocytic bronchiolitis and peribronchiolitis with lymphoid hyperplasia. ξ Diagnosed 
as organizing pneumonia. Ψ With a granulomatous reaction. ¶ Pulmonary fibrosis has not been reported, but asthma might 
occur based on epidemiological studies.  Yoshida, Ohnuma, Horiuchi et al.﷿
(1287 °C) and high tensile strength, and these properties 
have  led  to  its  incorporation  into  many  high-technology 
applications  (e.g.,  electronics,  aerospace,  machinery  and 
nuclear weapons manufacture)8,9. Exposure to beryllium at 
workplaces continues to be a public health concern, with ap-
proximately one million individuals exposed and potentially 
at risk of developing acute beryllium disease (ABD) and 
chronic beryllium disease (CBD), both of which involve hy-
persensitivity reactions to beryllium10,11. Genetic suscepti-
bility to CBD has been linked to a major histocompatibility 
complex (MHC) class II isotype, human leukocyte antigen 
(HLA)-DP alleles, which contain a glutamic acid residue 
at amino acid position 69 in the b-chain12–14. Among the 
mouse strains FVB/N, AKR, Balb/c, C3H/HeJ, C57/BL6, 
DBA/2 and SJL/J, the FVB/N strain has been reported to 
be the least responsive, while the SJL/J and C57/BL6 strains 
have been shown to be the highest responders15.
CBD  is  characterized  by  the  presence  of  noncapsu-
lating  granulomatous  inflammation  in  the  lung  and  sub-
sequent development of progressive fibrosis16. Accumulat-
ing evidence clearly suggests that CBD is recognized as 
an immune-mediated granulomatous reaction. Six to nine 
months after a single exposure of A/J and C3H/HeJ mice to 
beryllium for 90 min, lung responses comprised interstitial 
aggregates of lymphocytes—B cells centrally and T cells 
peripherally—and granulomatous pneumonia characterized 
by intra-alveolar foamy macrophages, giant cells and neu-
trophils, and multifocal interstitial granulomas17. Evidence 
suggests  that  recruitment  of  beryllium-specific  CD4+  T 
cells to the lung significantly mediates the immunopatho-
genesis of CBD. These CD4+ T cells expressed an effector 
memory T cell phenotype10,13 and secreted the T helper 1 
(Th1)-type  cytokines  interferon-g  (IFN-g),  interleukin-2 
(IL-2) and tumor necrosis factor-a (TNF-a) upon beryllium 
exposure18–20. Programmed death-1, which is a member of 
the CD28 family and a negative regulator of T cell function, 
was expressed at significantly high levels in bronchoalveo-
lar lavage (BAL) CD4+ T cells from CBD patients, plausibly 
leading to induction of T cells and preventing activation-
induced cell death21. Lately, ABD has also been recognized 
as a specific lymphocytic alveolitis rather than a nonspecific 
inflammatory  process  of  an  irritant11.  Beryllium-specific 
CD8+ T cells may play a minor role, if any, in the pathogen-
esis of this disease, as inferred from the results of analysis 
of BAL samples from CBD patients10.
Beryllium-induced oxidative stress plays a role in the 
pathogenesis of granulomatous inflammation in CBD. A de-
crease in intracellular thiols, glutathione and cysteine was 
observed in peripheral blood mononuclear cells from beryl-
lium-sensitized and CBD patients, and beryllium-mediated 
T cell proliferation was inhibited by the thiol antioxidant 
N-acetylcysteine and the catalytic antioxidant manganese 
(III) in vitro22. Increased glutathione in lung epithelial lin-
ing fluid from CBD patients is correlated with glutathione 
peroxidase activity23. Heme oxygenase-1 (HO-1) activity is 
also increased in induced sputum from CBD patients24. To-
gether, the data imply that augmentation of glutathione- and 
HO-1-mediated antioxidant systems may be involved in the 
process of CBD.
Although cellular and molecular mechanisms underly-
ing berylliosis have been investigated, the exact profibro-
genic factors have not been identified thus far. Mast cells 
may contribute to the pathogenesis of CBD, serving as an 
important source of a 17.8-kDa isoform of basic fibroblast 
growth factor, which is a potent mitogenic and chemotactic 
factor, regulating fibroblast proliferation and ECM produc-
tion25. In contrast, beryllium at low concentrations inhibits 
the growth of normal human fibroblasts, as proved by G0-
G1/pre-S phase arrest and senescence associated with eleva-
tion of the p53, p21 and p16 levels26,27. At high concentra-
tions, beryllium is somewhat carcinogenic to BALB/c-3T3 
cells (mouse embryonic fibroblast cell line)28. TGF-b signal-
ing in CBD has not been fully investigated, although Jonth 
et al.﷿ (2007) have reported that the codons -509 C and 10T, 
implicated in the production of low levels of TGF-b1 pro-
tein, are shared susceptibility factors associated with more 
severe granulomatous inflammation in CBD29. Thus, inves-
tigations  of  profibrogenic/antifibrogenic  signaling  would 
provide a better understanding of the pathobiology of CBD 
and aid in exploring therapeutic targets.
Nylon Flock and Textile Paints
Flock  is  cut  or  pulverized  fiber—synthetic  or  natu-
ral—of small diameter that produces a velvet-like coating 
when applied to an adhesive-coated fabric or other material. 
Flocked fabrics of nylon (polyamide), rayon (cellulose ac-
etate), Dacron (ethylene glycol-terephthalic acid) and poly-
ester fibers are becoming increasingly popular, especially 
as upholstery coverings and blankets. Kern et al.﷿ (2000) 
reported a chronic nongranulomatous ILD termed “Flock 
Worker’s  Lung”  in  nylon  flocking  industry  workers  at  a 
Rhode Island plant in the 1990s30. The workers developed 
BAL eosinophilia, NSIP, OP and/or lymphocytic bronchiol-
itis and interstitial fibrosis. A small number of North Ameri-
can patients have also been reported to have nylon flock-
related DIP. At a clinical pathology workshop hosted by 
the National Institute for Occupational Safety and Health, 
consulting pulmonary pathologists diagnosed “lymphocytic 
bronchiolitis  and  peribronchiolitis  with  lymphoid  hyper-
plasia” in workers at 5 nylon flock facilities in 3 different 
U.S. states and a Canadian province, on the basis of clinical 
examination and histopathological findings31. This descrip-
tive terminology was supported by the Centers for Disease 
Control (CDC) at a clinical-pathological workshop hosted 
by the CDC32.
Although nylon fibers may act as haptens and trigger an 
allergic reaction (e.g., occupational asthma)33, in vivo exper-
iments have failed to demonstrate pulmonary hypersensitiv-
ity reactions to nylon. Airborne dust (nylon flock) collected 
at a nylon flocking plant interacted with alveolar macro-
phages and induced mild-to-moderate, multifocal, suppu-
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rative  pneumonia  around  bronchioles  after  intratracheal 
instillation in rats (10 mg/kg body weight)34. In rats exposed 
to aerosols of uncoated, finish-free nylon respirable-sized, 
fiber-shaped particulates at 6 hours per day and 5 days per 
week for 4 weeks, there were no significant increases in lung 
weight, indications of pulmonary inflammation or alveolar 
macrophage functional deficits, as compared with the con-
trol rats35. Thus, since workers exposed to high concentra-
tions of nylon fiber dust may be at an increased risk of ILDs, 
suitable animal models should be developed to clarify the 
role of nylon flock in immune-based pulmonary diseases.
Synthetic fibers do not include metals. Synthetic fibers 
present an insoluble solid-liquid interface to the surround-
ing host tissue, and the fiber surface includes functional 
groups having the ability to mobilize metal from endoge-
nous sources, introducing a metal-catalyzed oxidative stress 
in the lower respiratory tract. Ghio et al.﷿ (2006) reported 
that a ferruginous body, with its accumulated iron, func-
tions as an indicator of both metal accumulation and as a 
potential oxidative stressor36. The clinical presentations of 
2 patients employed in a textile mill were consistent with 
a chronic fibrotic disease of the lung, in which there were 
areas of traction bronchiectasis with chronic inflammation 
and bronchial metaplasia and bronchiolitis with mixed lym-
phocytic and eosinophilic infiltration. Staining of resected 
tissue for iron revealed structures having the appearance of 
ferruginous bodies. Energy dispersive X-ray analysis and 
scanning electron microscopy revealed that the fibers iso-
lated from the lung were carbonaceous and originated from 
the mill. Thus, metal, particularly iron, may play a role in 
the pathogenesis of Flock Worker’s Lung.
Besides synthetic fibers, textile paints may affect hu-
man health in these industries. An outbreak of severe re-
spiratory disease called “Ardystil syndrome” occurred in 
the Community of Valencia, Spain, among factory workers 
who worked where textiles were air-sprayed with dyes by 
using the Acramin F paint system. Twenty-two cases of OP 
were identified, and of the 22 patients, 6 died within a few 
months37. Besides OP, interstitial fibrosis and DAD were 
evident38. In another study, after a 1 year follow-up of 27 
patients heavily exposed to textile sprays, symptoms were 
observed  to  persist  in  15  cases39.  The  main  polycationic 
components of textile sprays are Acramin FWR (a poly-
urea),  Acramin  FWN  (a  polyamide-amine)  and  Acrafix 
FHN (a polyamine), and the non-polycationic component is 
Acramoll W. Acramin FWR, Acramin FWN and Acrafix 
FHN exhibited considerable toxicity in rat and human type 
II pneumocytes and alveolar macrophages, while Acramoll 
W was almost nontoxic40. Consistent with the results of in 
vitro experiments, lung damage was caused by Acramin 
FWR, Acramin FWN, Acrafix FHN or their mixture after 
intratracheal instillation in hamsters41. Protein concentra-
tion, lactate dehydrogenase (LDH) activity, inflammatory 
cell number and percentage of polymorphonuclear neutro-
phils were increased in BAL fluid during the first week, 
and lung weight remained high for at least a month after 
intratracheal instillation. Inflammatory cell infiltration and 
subsequent fibrosis with collagen deposition were detected 
in lung histology, which was confirmed by increased hy-
droxyproline content in dried lung tissue. Acramoll W did 
not show toxic effects even in vivo. Interestingly, multiple 
positive charges might play an important role in the toxic-
ity mechanism of the polycations with no irritant properties, 
since the cytotoxicities decreased in the presence of polyan-
ions42. Overall, combined exposures to textile dyes and ny-
lon flock could be involved in development of the diseases, 
and cross-talk between them should be further investigated.
PVC
PVC is the second most commonly used plastic mate-
rial worldwide, and it is used in numerous products, e.g., 
credit cards, computer keyboards, flooring material, food 
containers, medical cannulae, telephones, highway sound 
barriers and toys. At the end of the synthesis process, the 
material  may  exist  as  respirable  dust,  the  inhalation  of 
which may result in lung function impairment. Epidemio-
logical  surveys  have  identified  PVC  dust  as  an  etiologic 
agent in dyspnea with decreased pulmonary function and 
appearance of opacities in chest radiograph43, in a particular 
type of pulmonary fibrosis with a granulomatous reaction44 
and in interstitial fibrosing pneumonia45. Electron micros-
copy revealed a nonhomogenous material in the cytoplasm 
of giant multinucleated cells and/or alveolar macrophages, 
which was identified to be PVC particles44,46,47. Human alve-
olar macrophages that engulfed PVC powder showed a simi-
lar ultrastructural appearance46. It is important to note that 
early PVC pneumoconiosis may regress in human cases48.
Several studies on PVC exposure to animals have been 
conducted, although there is no evidence of fibroprolifera-
tion in the lung. Rats, guinea pigs and monkeys were ex-
posed by inhalation (6 hours per day, 5 days per week) for 
22 months; autopsies of rats and guinea pigs and of monkeys 
were performed after 12 and 22 months of exposure, respec-
tively.  PVC  particles  were  found  in  aggregated  alveolar 
macrophages, but there were no other effects either on lung 
histology or pulmonary function49. Hoet and his colleagues 
have conducted detailed investigations of the effects of PVC 
exposure in vitro and in vivo. Emulsion of PVC particles 
with a mean diameter of 2 mm exhibited moderate toxicity 
in cultures of different pulmonary cells, i.e., rat and human 
alveolar macrophages, rat type II pneumocytes, A549 cells 
(type II cell type) and THP-1 cells (macrophage-like). It was 
found that the cytotoxicity and inflammatory potential of 
some PVC particles might be mostly due to their residual 
additives, since removal of the residual additives consider-
ably reduced their toxic effects50. However, in vivo experi-
ments did not confirm the conclusion from the in vitro tox-
icity tests. Male Wistar rats received a single intratracheal 
instillation of the washed “additive-free” PVC particles. As 
a result, they exhibited pulmonary inflammation and dam-
age similar to that in the silica-exposed rats at 2 days; how-13   Yoshida, Ohnuma, Horiuchi et al.﷿
ever, at 90 days, most parameters returned to the control 
level, except for minor histopathological lesions. Interest-
ingly, additive-free PVC particles caused less neutrophil but 
more eosinophil influx than the original PVC particles con-
taining residual detergents. The washed additive-free PVC 
particles might be more hydrophobic than the original PVC 
particles, but pulmonary eosinophilia was induced via an 
unknown mechanism51. Repeated intratracheal instillation 
of PVC particles for 3 weeks increased the number of CD4+ 
and CD8+ T cells in BAL fluid, and compared with the orig-
inal PVC particles, the additive-free PVC particles tended 
to induce more changes in many endpoints, including BAL 
eosinophilia52, as observed in the single intratracheal instil-
lation study51. Experimental BAL eosinophilia is apparently 
linked to asthma, as reported in epidemiological studies on 
PVC53,54. Together, deposition of PVC particles with or with-
out residual detergents in alveolar macrophages and subse-
quent immunoreactions may contribute to the development 
of PVC-induced pneumoconiosis.
DDAC
DDAC [C10H21N(CH3)2C10H21·Cl], a representative di-
alkyl quaternary ammonium compound (QAC), is used as 
a detergent in wood preservatives, as a disinfectant against 
pathogens and in other applications55–58. DDAC formulations 
are directly added to water in swimming pools, spas and hu-
midifiers and used for treatment of surfaces in institutional, 
commercial, industrial and residential settings by fogging, 
flooding, immersion, wiping, mopping, aerosol spray treat-
ment and low- and high-pressure spray treatments with final 
spray concentrations ranging from 0.5 to 26320 ppm59. The 
action of DDAC on the cell membrane causes leakage of 
intracellular molecules60, together with autolysis and sub-
sequent death of Escherichia coli and Staphylococcus au-
reus61. Occupational exposure to QACs, including DDAC, 
therefore, is known to cause contact dermatitis, conjunc-
tivitis62  and  asthma63–65  among  professionals  working  in 
healthcare and cleaning industries. Although DDAC does 
not  seem  to  contaminate  the  indoor  hospital  atmosphere 
during the disinfection process, it can contaminate working 
atmospheres if it is put in suspension by aerosolization66. 
The same health concerns are expected to exist for veteri-
nary professionals, since DDAC is a useful disinfectant for 
preventing the entry and spread of infectious disease agents, 
including enveloped and non-enveloped viruses, in domes-
tic animals67,68.
Recently, we reported that DDAC induces pulmonary 
injury and fibrosis in mice69. To our knowledge, this was 
the first report on pulmonary fibroproliferative response to 
topically applied DDAC. In mice with intratracheally in-
stilled DDAC, pulmonary cytotoxicity (increase in protein 
concentration and LDH activity in BAL fluid) was evident 
in association with inflammation, which was confirmed by 
the expression of monocyte chemotactic protein-1 (MCP-
1),  macrophage  inflammatory  protein  (MIP)-1a,  MIP-1b 
and regulated upon activation, normal T cell expressed and 
secreted (RANTES) in BAL fluid. These changes were ac-
companied  by  altered  gene  expression  of  the  chemokine 
(C–C motif) receptors Ccr1, Ccr2, Ccr3 and Ccr5 in the 
lung. Expression of chemokines might principally be de-
rived from alveolar macrophages, as in vitro cytotoxicity 
was higher in the macrophages (J774.1) than in epithelial 
cells (A549) and isolated mouse lung fibroblast (MLF)-like 
cells (Ohnuma et al.﷿, unpublished data). The cytotoxic and 
inflammatory  phases  were  accompanied  or  followed  by 
pulmonary remodeling, i.e., fibrosis, which was evident by 
an increase in interstitial connective tissue and fibroblasts/
myofibroblasts,  as  demonstrated  by  Masson’s  trichrome 
stain;  immunohistochemistry  for  a-smooth  muscle  actin 
(a-SMA); and mRNA expression of type I procollagen69. 
Overall, pulmonary injury peaked in the first week after a 
single instillation of DDAC in the lung; fibroproliferation 
gradually became profound in the first week and peaked in 
the second week, subsequently reducing in the third week 
(Fig 1). The role of TGF-b and BMP in fibrogenesis is cur-
rently being investigated in our laboratories.
Limited toxicology information is currently available 
for  DDAC59,70.  Similar  to  DDAC,  benzalkonium  chloride 
(BAC)  is  a  mixture  of  alkylbenzyldimethylammonium 
chlorides belonging to the QAC group and is widely used as 
a disinfectant and in preservatives and stabilizers. Rats that 
aspirated BAC following oral administration showed AIP71. 
Furthermore, BAC inhalation caused strong inflammation 
via an irritant activity, as demonstrated by an increase in 
lung weight and high levels of total protein, LDH activity, 
matrix  metalloproteinase-9  (MMP-9),  TNF-a  and  MIP-2 
in BAL fluid; however, no histopathological examinations 
were carried out72. The mode of action of DDAC and BAC 
hypothetically poses human health concerns, particularly if 
people are unknowingly exposed to these QACs or experi-
ence prolonged workplace exposure. In our current protocol, 
a similar sequence of pulmonary changes as those occurring 
in bleomycin- or fluorescein isothiocyanate (FITC)-induced 
lung injury73–77 was observed on DDAC administration; it 
seemed that the fibrotic response to DDAC administration 
was more rapid, but weaker, than that to bleomycin or FITC 
treatment. This unique property of pulmonary responses 
would be helpful in better understanding pulmonary fibrotic 
diseases particularly at promoting and regenerating phases.
Molecular Targets Involved in the Pathogenesis 
of Pulmonary Fibrosis
Chemokines and CCRs
Inflammatory  reactions,  involving  an  influx  of  par-
ticular  cell  types  expressing  cytokines,  chemokines  and 
cell surface molecules, precede and accompany pulmonary 
fibrosis, whereas nonspecific inflammatory processes end 
with nonfibrous tissue repair78. Several cytokines and che-
mokines and their receptors have been investigated with re-
gard to their contribution to the pathogenesis of pulmonary 14 Profibrotic Environmental Cues
fibrosis in human and animal models75,79–82.
Murine MCP-1, also known as JE or chemokine (C–C 
motif) ligand 2 (CCL2), is considered homologous to human 
CCL2, which is produced by a variety of cells, including en-
dothelial cells, fibroblasts, monocytes, and smooth muscle 
cells83. MCP-1 and its receptor CCR2 are involved in fibrosis 
via regulation of profibrotic cytokine generation and ECM 
formation84–86. This is supported by the fact that CCR2-
knockout mice with FITC- or bleomycin-induced pulmo-
nary fibrosis showed improvement in fibrosis74,87. The pro-
tective effect was associated with suppressed macrophage 
infiltration  and  macrophage-derived  MMP  production88 
and enhanced alveolar epithelial cell inhibition of fibroblast 
proliferation89. CCR2 also mediates neutrophil recruitment 
through effects on intravascular adherence and subsequent 
transmigration90. Surprisingly, MCP-1 binds not only to al-
veolar macrophages but also to bone marrow-derived fibro-
cytes, both of which express CCR291. Interestingly, trans-
plant of CCR2+/+ bone marrow cells into CCR2–/– recipients 
restored recruitment of lung fibrocytes and susceptibility 
to FITC-induced fibrosis. The study showed that fibrocytes 
may contribute to fibrogenesis in several ways: (1) fibro-
cytes may directly contribute to fibrosis by secreting col-
lagen, since the amount of collagen secreted by CCR2+/+ 
fibrocytes exposed to MCP-1 was greater than that secreted 
by CCR2–/– fibrocytes; (2) fibrocytes secrete TGF-b1, and 
thus, CCR2-mediated recruitment of fibrocytes to the lung 
may serve to activate resident fibroblasts via the secretion 
of TGF-b1; and (3) fibrocytes may differentiate into effec-
tor fibroblasts. Murine MCP-5/CCL12, which is homologous 
to human CCL2, may have a higher affinity for activated 
macrophages than MCP-192. Moore et al.﷿ (2006) proposed 
that MCP-5 rather than MCP-1 is more likely to drive fi-
broproliferation  in  mice  via  its  interaction  with  CCR293. 
Inconsistent with this, Tsou et al.﷿ (2007) demonstrated that 
MCP-1 and MCP-3, rather than MCP-2 and MCP-5, are the 
CCR2 agonists that are most critical for the maintenance 
of monocytes94. Thus, although the contribution of CCR2 
agonists remains controversial, the MCP/CCR2 system may 
represent the link between the macrophage-dominant phase 
and the subsequent remodeling phase.
CCR1 is constitutively expressed on monocytes, neu-
Fig. 1.  DDAC induces inflammation and fibroproliferation in the lungs. Mice were intratracheally instilled with 0.01% of DDAC or the vehicle 
control and were sacrificed on day 7, 13, or 20 after the treatment69. Lung tissue samples were subjected to histopathological examina-
tion. Representative images of the lung tissues stained with hematoxylin and eosin (A–D) and Masson trichrome (E–H) from the vehicle 
control (A, E) and DDAC-treated mice on day 7 (B,F), 13 (C,G) or 20 (D,H). Scale bar: 50 µm.15   Yoshida, Ohnuma, Horiuchi et al.﷿
trophils, lymphocytes and eosinophils and interacts with 
MIP-1a,  RANTES,  MCP-2  and  MCP-383,95.  After  bleo-
mycin challenge in mice, CCR1 mRNA levels and CCR1-
positive cells increased and peaked on day 7, which paral-
leled the expression of MIP-1a and RANTES73. Anti-CCR1 
antibody  inhibited  inflammatory  cell  accumulation  and 
collagen deposition, resulting in dramatic improvement in 
survival. In contrast, bleomycin-induced an increase in in-
trapulmonary macrophage and fibrocyte numbers, and col-
lagen deposition was attenuated in MIP-1a–/– mice but not 
in CCR1–/– mice77. CCR1 was observed to play a limited 
role in pulmonary granuloma formation, since the granu-
loma size remained unchanged in CCR1–/– mice, as com-
pared with CCR1+/+ mice, challenged with Sepharose beads 
coupled to the purified protein derivative of Mycobacterium 
bovis or soluble antigens derived from Schistosoma man-
soni eggs96. However, natural killer (NK) cell recruitment 
and Th1 response (expression of IL-2 and IFN-g) were re-
duced, while Th2 response (expression of IL-5 and IL-13) 
was enhanced in CCR1–/– mice in comparison with CCR1+/+ 
mice. Thus, CCR1 seemed to be critical in immune-medi-
ated fibrotic disease, and this was supported by the fact that 
airway remodeling, e.g., goblet cell production and subepi-
thelial fibrosis, was absent in CCR1–/– mice during chronic 
fungal allergic airway disease97. Rather than CCR1, CCR5, 
another receptor of MIP-1a, seemed to be critical in regu-
lating fibrosis, since CCR5–/– mice showed attenuation of 
collagen deposition and macrophage infiltration induced by 
bleomycin77.
CCR3 is highly expressed on neutrophils and eosino-
phils, and its ligand is eotaxin-1/CCL1183,95. Administration 
of bleomycin induces a marked pulmonary expression of 
eotaxin-1 and CCR376. Eotaxin-1–/– mice showed reduced 
pulmonary fibrosis associated with a decrease in TGF-b1 
mRNA  expression,  whereas  increased  expression  of  eo-
taxin-1 by using eotaxin-1-expressing adenovirus enhanced 
bleomycin-induced  lung  fibrosis.  Similar  to  eotaxin-1–/– 
mice,  those  treated  with  neutralizing  CCR3  antibodies 
showed reduced pulmonary fibrosis, eosinophilia, neutro-
philia and TGF-b1 mRNA expression.
CCR4 is a selective marker for Th2 lymphocytes and 
is expressed in dendritic cells, NK cells and monocytes; 
thymus-  and  activation-regulated  chemokine  (TARC)/
CCL17 and macrophage-derived chemokine (MDC)/CCL22 
are  both  high-affinity  ligands  and  high-potency  agonists 
for  CCR483,95,98.  The  mRNA  and  protein  expressions  of 
TARC and MDC were elevated in lung tissues after bleo-
mycin treatment, which was related to alveolar expression 
of CCR499. Neutralization of TARC, but not MDC, led to a 
reduction in collagen deposition and BAL leukocytes, in-
cluding CD4+ T cells, CD8+ T cells, NK cells, macrophages 
and neutrophils. TARC was expressed in alveolar epithelial 
cells in the lung tissues of bleomycin-treated mice and hu-
man patients with IPF. These data support the results of an 
experiment conducted using CCR4–/– mice, which protected 
from bleomycin-induced lethal inflammatory and fibrotic 
responses, with evidence of a reduction in the TARC and 
MDC levels observed in lung homogenates100. A major con-
tribution to this protective effect might be the regulatory role 
of CCR4 in determining the phenotype of macrophages dur-
ing the acute inflammatory phase by switching classically 
activated or M1 macrophages (type-1 polarization, induced 
by Th1 signals, i.e., IFN-g expression) to alternatively acti-
vated or M2 macrophages (type-2 polarization, induced by 
Th2 signals, i.e., IL-4 and IL-13 expression). In the presence 
of CCR4, TARC and MDC promoted tissue injury through 
induction of the M1 macrophage phenotype with increased 
nitric oxide synthase 2 (NOS2) and decreased arginase 1 
expression; in the absence of CCR4, M2 macrophage activa-
tion occurred through suppression of NOS2 and increased 
expression of arginase 1 and found in inflammatory zone 
1 (FIZZ1), favoring upregulation of a decoy receptor, D6, 
which attenuates inflammation and tissue injury by inter-
nalizing and degrading chemokines. Thus, it appears that 
alterations in M1/M2 marker expression are confined to the 
early inflammatory stage and that the establishment of a 
fibrotic process is not necessarily associated with M2 po-
larization101. Furthermore, reduction in arginase 1 in lung 
epithelial cells enhanced the levels of NO metabolites and S-
nitrosylated proteins and resulted in increased TNF-a- or li-
popolysaccharide (LPS)-stimulated nuclear factor-kB (NF-
kB) DNA binding102. Coculture of FIZZ1-expressing type II 
alveolar epithelial cells with fibroblasts stimulates a-SMA 
and type I collagen expression independent of TGF-b103 and 
dependent on Notch/Jagged 1104. The imbalance of arginase 
1 and NOS2 in association with the induction of FIZZ1 may 
contribute to fibrogenesis, depending on the stage of inflam-
mation and specific cell types.
CCR7 is expressed by T and B cells and plays an im-
portant role in T cell and dendritic cell trafficking in associ-
ation with its ligands, Epstein-Barr-induced 1 (EBI1)-ligand 
chemokine  (ELC)/CCL19  and  secondary  lymphoid-tissue 
chemokine (SLC)/CCL2183,98. CCR7 expression is raised in 
a severe form of IIP, UIP, and localized to focal areas con-
sisting of activated resident fibroblasts, rather than myofi-
broblasts and bone marrow-derived fibrocytes105. This was 
supported by Pierce et al.﷿ (2007), who showed that CCR7 is 
expressed by primary IPF/UIP fibroblasts but not by normal 
fibroblasts. IPF/UIP fibroblasts showed migration and pro-
liferation in response to CCR7 activation by SLC, but not by 
ELC, and SLC-mediated CCR7 activation seemed to be lim-
ited to the extracellular signal-regulated kinase (ERK)1/2 
and 90-kDa ribosomal S6 kinase (p90RSK) pathways, since 
the p38 mitogen-activated protein kinase (MAPK) and c-
Jun N-terminal kinase (JNK) pathways were not activated 
by SLC106. The investigators adopted an unusual technique 
to clarify the role of SLC/CCR7 axis elegantly. IPF/UIP 
fibroblasts,  NSIP  fibroblasts  and  normal  fibroblasts  were 
intravenously injected into severe combined immunodefi-
ciency (SCID) mice lacking adaptive and innate immune 
features. Interestingly, the mice with IPF/UIP fibroblasts 
showed patchy interstitial fibrosis and those with NSIP fi-16 Profibrotic Environmental Cues
broblasts showed a more diffuse interstitial fibrosis, with an 
increased hydroxyproline content in both cases. The inject-
ed normal fibroblasts did not induce interstitial remodeling. 
Neutralization of SLC or CCR7 attenuated pulmonary fibro-
sis in mice that received either type of fibroblasts. However, 
delayed onset of pulmonary remodeling, which was noted at 
35 days after intravenous injection, remains to be clarified. 
Similarly, Trujillo et al.﷿ (2010) showed that CCR7–/– mice 
were protected from bleomycin-induced pulmonary fibro-
sis; the effect was related to an early increase in lung CD4+ 
T cells and late increase in CD4+CD25+FoxP3+ Tregs, which 
was consistent with increased IL-2 expression107, indicating 
that CCR7-independent Tregs expansion is a novel therapeu-
tic target for pulmonary fibrosis.
Tregs
T cells are present in the lungs of patients with pulmo-
nary fibrosis because a variety of causes play a pivotal role 
in the fibrotic process. CD4+ T cells are abundant in the lung 
in granulomatous lung diseases such as IPF, sarcoidosis and 
berylliosis10,13,108. In fact, CD4+ T cells from IPF patients 
have characteristics typical of cell-mediated pathologic re-
sponses, including augmented effector functions (produc-
tion of TGF-b1, IL-10 and TNF-a), provision of facultative 
help for immunoglobulin G (IgG) autoantibody production, 
oligoclonal expansions and proliferations driven by an an-
tigen present in diseased tissues109. Most previous studies 
investigated whole T cells, while the emerging novel sub-
populations of naturally occurring and adaptive Tregs take 
the center stage as the crucial immunoregulatory cells that 
are capable of suppressing Th1- and Th2-mediated adaptive 
immune responses in a cell contact-dependent fashion di-
rectly or by acting on antigen-presenting cells110. Since the 
transcription factor Foxp3 has been shown to be selectively 
expressed in Tregs in humans and mice, Foxp3 mRNA rep-
resents a more specific marker than cell surface molecules 
such as CD25, cytotoxic T lymphocyte-associated antigen 
4  (CTLA-4)  and  glucocorticoid-induced  TNF  receptor 
(GITR)111–114.
In CBD and beryllium-sensitized patients, a small pop-
ulation of BAL CD4+ T cells retained CD27 expression, and 
these CD4+CD27+ T cells contained the FoxP3-expressing 
naturally occurring Treg subset, increasing T cell expansion, 
while the vast majority of CD4+ T cells had lost surface CD27 
expression, which inversely correlated with lung inflamma-
tion in the patients115. The number of CD4+CD25+FOXP3+ 
Tregs and their activities (demonstrated by Th1- and Th2-cy-
tokine expression) were reduced in both BAL and peripheral 
blood of patients with IPF as compared with those of healthy 
volunteers and patients without IPF; further, the defective 
function of BAL Tregs highly correlated with the parameters 
of disease severity, as determined by pulmonary function 
tests116. Furthermore, downregulation of CD28, which in-
duces FoxP3 and generates CD4+CD25+ Tregs, was evident 
in IPF patients, and these patients demonstrated infiltrations 
of CD4+CD28null T cells in lung tissues and a positive cor-
relation between the presence of these cells and indication 
of lung transplantation or death in the next year117. Thus, the 
data suggested that Tregs play a pivotal role in pulmonary 
fibrosis; however, additional studies extensively addressing 
Treg interactions with cellular and soluble factors in animal 
models and human patients are required, since it has been 
reported that Treg depletion accelerates in vitro granuloma 
growth in mononuclear cell cultures of healthy controls but 
not in those of patients with active sarcoidosis118.
TGF-b and BMP signaling
TGF-b1  has  the  ability  to  induce  the  expression  of 
ECM  proteins  in  mesenchymal  cells119.  Cellular  TGF-b1 
mRNA levels were higher than cellular TGF-b2 and TGF-
b3 mRNA levels in IPF patients120 and bleomycin-treated 
mice121. However, TGF-b2 and TGF-b3 have the potential 
for in vitro fibrogenic activity that is the same as or higher 
than the in vitro fibrogenic activity of TGF-b1122. Signaling 
by TGF-b family members occurs via TGF-b type I and type 
II receptors (TGF-bRI and TGF-bRII, respectively)119,123,124. 
Upon phosphorylation by activated TGF-bRI/activin recep-
tor-like kinase-5 (ALK-5), TGF-b-activated Smad2/Smad3 
forms a heteromeric complex with Smad4, which is trans-
located to the nucleus where it functions as a transcription 
factor. Smad3, in particular, is of critical importance in the 
development of fibrosis124,125, since loss of Smad3 greatly 
attenuated histopathological fibrotic responses to bleomy-
cin126  or  active  TGF-b1-expressing  adenovirus127  in  the 
mouse lung. Active TGF-b1 is a major cytokine that stimu-
lates transcription of the Col1a2 gene, as determined by the 
binding of Smad3-Smad4 complex to the cis-element TGF-
b-responsive element (TbRE) in the proximal promoter re-
gion128.
It is important to note that repression of collagen gene 
expression is critical for pulmonary disease therapy, and 
lately,  two  complex  underlying  mechanisms  have  been 
proposed by Xu et al.﷿ (2006, 2007): methylation-mediated 
repression may be mediated by interaction of the regula-
tory factor for X-box 1 (RFX1) and histone deacetylase 1 
(HDAC1) at the TATA box, or IFN-g-mediated repression 
may be mediated by the interaction of RFX5, class II trans-
activator,  HDAC2,  and  peroxisome  proliferator-activated 
receptor g at the CCAAT and TATTA boxes129,130. Lin et al.﷿ 
(2006)  identified  protein  phosphatase  1A  (PP1A)/PP2Ca 
as  a  Smad2/Smad3  SXS  motif-specific  phosphatase  that 
inhibits  Smad2/Smad3  phosphorylation131.  Interestingly, 
phosphatase and tensin homolog (PTEN) deleted on chro-
mosome 10 plays a negative role in the TGF-b pathway by 
forming a complex with PP1A/PP2Ca132. A lipid mediator, 
sphingosine 1-phosphate (S1P), mimics TGF-b-induced cell 
responses  through  cross-activation  of  Smad  signaling133 
or  Rho  signaling134  cascades,  while  dihydrosphingosine 
1-phosphate  (dS1P)  plays  an  opposite  role  in  the  regula-
tion of TGF-b signaling by stimulating phosphorylation of 
PTEN  and  its  subsequent  translocation  to  the  nucleus132. 
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regulation of TGF-b/Smad signaling through formation of a 
PP1A/PP2Ca-PTEN complex, probably mediated by dS1P, 
may open the possibilities to control the progression of pul-
monary fibrosis.
Further,  TGF-b  terminates  the  induction  of  its  own 
target genes by induction of Smad7, which competes with 
Smad2  and  Smad3  for  binding  to  TGF-bRI125;  inhibits 
receptor-activated  Smad2  phosphorylation135;  recruits  the 
E3 ubiquitin ligases Smurf1, Smurf2, Nedd4-2 and WW 
domain-containing  protein  1  (WWP1)/Tiul1  to  TGF-bRI 
and  Smads,  causing  their  degradation136;  or  specifically 
binds to the Smad-responsive element via its Mad homol-
ogy 2 (MH2) domain and disrupts formation of a TGF-b-
induced  functional  Smad-DNA  complex137.  As  expected, 
a decrease in the expression of Smad7 was observed after 
bleomycin instillation in rats, in contrast to a persistent in-
crease in the phosphorylation and nuclear localization of 
Smad2/Smad3138. The same groups compared the levels of 
phosphorylated Smad3 and Smad7 in isolated fibroblasts 
from the lungs of control and bleomycin-treated rats under 
normal conditions and after TGF-b treatment139. The basal 
levels  of  phosphorylated  Smad3  were  higher  in  the  nor-
mal lung fibroblasts than in bleomycin-treated lung fibro-
blasts, but the basal levels of Smad7 were comparable. After 
TGF-b treatment, the levels of phosphorylated Smad3 and 
Smad7 mRNA were increased in both treated and normal 
cells, while the protein level of Smad7 was increased in the 
normal lung fibroblasts as compared with the bleomycin-
Fig. 2.  Proposed concept of toxicological pulmonary granuloma and fibrosis as lung diseases induced in response 
to environmental cues. Chemicals have the potential to function as either antigens or irritants or both for 
alveolar macrophages, dendritic cells and/or epithelial cells. Antigens are presented to T cells by APCs, 
inducing Th1-type inflammation (expressing TNF-a, IFN-g and IL-2) and recruiting many CD4+ and CD8+ 
T cells, which may contribute to the formation of giant and epithelioid cells. Only a few Tregs are found in 
affected humans and animals as compared with the controls, subsequently disturbing the Th1/Th2 balance. 
On the other hand, cytotoxicity by irritants induces inflammation in association with the expression of 
chemokines (MIP-1a, MCP-1, MCP-3, MCP-5, eotaxin-1, TARC, MDC, ELC and SLC) and recruitment of 
macrophages, PMN and lymphocytes (T cells/B cells), followed by the proliferation of fibroblasts and myo-
fibroblasts. Circulating fibrocytes derived from the bone marrow contribute to fibrotic disorders in the lung. 
Profibrotic and antifibrotic signaling may be regulated by TGF-b/BMP/gremlin and PP1A/PTEN signaling. 
APCs, antigen-presenting cells; Th1, T helper 1; TNF-a, tumor necrosis factor-a; IFN-g, interferon-g; IL-2, 
interleukin-2; Tregs, regulatory T cells; Th2, T helper 2; MIP, macrophage inflammatory protein; MCP-1, 
monocyte chemotactic protein-1; TARC, thymus- and activation-regulated chemokine; MDC, macrophage-
derived chemokine; ELC, Epstein-Barr-induced 1 (EBI1)-ligand chemokine; SLC, secondary lymphoid-tis-
sue chemokine; PMN, polymorphonuclear neutrophils; TGF-b, transforming growth factor-b; BMP, bone 
morphogenetic protein; PP1A, protein phosphatase 1A; PTEN, phosphatase and tensin homolog.18 Profibrotic Environmental Cues
treated lung fibroblasts. The investigators concluded that 
inadequate response to TGF-b and consequent imbalance 
between the levels of Smad7 and phosphorylated Smad3 
might contribute to the fibrotic phenotype characteristic of 
activated fibroblasts. In fact, bleomycin-induced collagen 
deposition and phosphorylation of Smad3 were prevented 
by an intratracheal injection of a recombinant adenovirus 
carrying mouse Smad7 cDNA140. Intriguingly, inhibition of 
TGF-b2 release by IFN-g141 and myofibroblast differentia-
tion by hepatocyte growth factor (HGF)142 has been report-
ed to be dependent on Smad7. Overall, overexpression of 
Smad7 may be a therapeutic target for IIPs.
BMPs member, one of the TGF-b family, have been in-
vestigated in pulmonary vascular disorders, especially pul-
monary hypertension, which has been linked to mutations 
in the BMP receptor II gene123 and expression of BMP-2 and 
BMP-4. BMP-2 expression is increased by proinflamma-
tory stimuli and induces endothelial dysfunction, oxidative 
stress, and endothelial activation, including increased adhe-
sion of a monocyte cell line143. BMP-4 promotes migration 
of vascular smooth muscle cells, possibly contributing to 
vascular remodeling, i.e., medial wall thickening and mus-
cularization of vessel walls144. Lately, the role of BMPs, par-
ticularly BMP-7 and BMP-4, and that of gremlin in pulmo-
nary fibrosis has been investigated. BMP-7 is known to act 
as an antagonist of TGF-b1-dependent fibrogenic activity 
in mouse pulmonary myofibroblasts by inducing inhibitor 
of differentiation 2145, which is an important myoepithelial 
cell marker during epithelial-mesenchymal transition146,147. 
However, the role of BMP-7 in fibrosis remains controver-
sial, since BMP-7 treatment significantly reduced the hy-
droxyproline content in asbestos-treated mice148 but not in 
bleomycin-treated mice149. No alterations in BMP-4 levels 
have been reported in lung samples of IPF patients, but IPF 
fibroblasts are less responsive to exogenous BMP-4, which 
inhibits the growth of and induces apoptosis in myofibro-
blasts120. However, BMP-4 and BMP-7 accurately regulate 
fibrogenesis in different ways: BMP-4, but not BMP-7, re-
duces TGF-b1-induced ECM production, while BMP-7, but 
not BMP-4, inhibits TGF-b1-induced myofibroblast trans-
formation in normal human lung fibroblasts150. On the other 
hand, TGF-b1 induces the expression of a BMP inhibitor, 
gremlin, in A549 lung epithelial cells, and IPF fibroblasts 
and their lung samples show high levels of gremlin mRNA 
and protein120,148. Pulmonary gremlin mRNA levels were 
also  upregulated  in  asbestos-treated  mice148.  Increased 
gremlin level may decrease BMP-4-mediated myofibroblast 
apoptosis and increase TGF-b signaling through suppression 
of BMP signaling. This concept was supported by evidence 
of latent TGF-b-binding protein-4–/– fibroblasts, which ex-
hibited reduced activation of TGF-b due to increased ex-
pression of BMP-4 and decreased expression of gremlin151. 
Thus,  profibrotic  and  antifibrotic  signaling  regulated  by 
TGF-b and BMPs and the role of gremlin in disrupting the 
balance between both the mediators provides the complex 
feedback loop coordinating fibrogenesis152.
Conclusion
The mechanism by which cytotoxicity and inflamma-
tion cause fibrosis in the lung in response to environmen-
tal cues is not fully understood. In most pulmonary fibrotic 
conditions, cytotoxicity, inflammation and repair could be 
dysregulated by imbalance in the production of chemokines, 
cytokines and growth factors, and pulmonary wound repair 
is an extremely dynamic process intersecting immunology, 
structural biology and airway physiology153. When a cyto-
toxic effect is minimal or self-limiting, repair would pro-
ceed to restore the normal structure, but when an injury is 
more extensive, tissue repair might result in scarring and/
or fibrosis154. The significance of new discoveries in un-
derstanding the pathogenesis of diseases and the potential 
molecular targets involved in advancing or interfering with 
fibrogenesis continues to be evaluated using in vivo analy-
ses of animal models substituting for patients with ILDs/
DPLDs155. Important advances have been made in identify-
ing molecules that are able to inhibit or induce lung granu-
lomas and fibrosis, including TGF-b and BMP signaling and 
chemokines and their receptors in relation to reduction in 
Tregs (Fig. 2). Evidence by toxicological approaches would be 
expected to explore new aspects of the pulmonary diseases. 
Exposure to beryllium causes a Th1 cytokine (TNF-a, IFN-
g and IL-2)-dominant granulomatous process, which might 
share the features of sarcoidosis, a more frequent disorder 
with similar pathological features156,157. Discovering the role 
of Tregs in CBD provides new insights in the mechanism of 
development of granulomatous lesions. On the other hand, 
nongranulomatous fibrosis has been found in nylon flock-
exposed individuals, with or without textile paint exposure, 
although experimental data are quite limited as of 2010. 
PVC is known to be an etiological agent of pneumoconiosis, 
including granulomatous or nongranulomatous fibrosis, and 
of lung cancer, hepatic angiosarcoma and leukemia/lym-
phoma158. QACs, including DDAC, may cause pulmonary 
diseases such as asthma or fibrosis, as shown by etiological 
research63–65 and our experimental study69. Because there 
are several types of ILDs/DPLDs (Table 1), there should be 
a note of caution regarding the pathological characteristics 
in human and animal cases.
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